• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Implications of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

作者信息

Wolff Antonio C, Tung Nadine M, Carey Lisa A

机构信息

The Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD.

Beth Israel Deaconess Medical Center, Boston, MA.

出版信息

J Clin Oncol. 2019 Sep 1;37(25):2189-2192. doi: 10.1200/JCO.19.01159. Epub 2019 Jun 3.

DOI:10.1200/JCO.19.01159
PMID:31157582
Abstract
摘要

相似文献

1
Implications of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.新辅助治疗在人表皮生长因子受体2阳性乳腺癌中的意义
J Clin Oncol. 2019 Sep 1;37(25):2189-2192. doi: 10.1200/JCO.19.01159. Epub 2019 Jun 3.
2
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.曲妥珠单抗、帕妥珠单抗和化疗新辅助治疗与曲妥珠单抗恩美曲妥珠单抗和帕妥珠单抗联合用于 HER2 阳性乳腺癌患者（KRISTINE）：一项随机、开放标签、多中心、III 期临床试验。
Lancet Oncol. 2018 Jan;19(1):115-126. doi: 10.1016/S1470-2045(17)30716-7. Epub 2017 Nov 23.
3
Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.ado曲妥珠单抗（ado-曲妥珠单抗）：一种HER2阳性靶向抗体药物偶联物。
Ann Pharmacother. 2014 Nov;48(11):1484-93. doi: 10.1177/1060028014545354. Epub 2014 Jul 31.
4
Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.ado曲妥珠单抗（T-DM1）：一种用于治疗HER2阳性转移性乳腺癌的新型抗体药物偶联物。
J Oncol Pharm Pract. 2015 Apr;21(2):132-42. doi: 10.1177/1078155214527144. Epub 2014 Mar 27.
5
De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.人表皮生长因子受体 2（HER2）阳性早期乳腺癌（BC）的降级策略：德国西部研究组辅助动态标志物调整个体化治疗试验的最终分析，该试验优化了早期 BC 的 HER2 和激素受体阳性患者的风险评估和治疗反应预测，随机 II 期试验比较了曲妥珠单抗恩坦辛联合或不联合内分泌治疗（ET）与曲妥珠单抗加 ET 的新辅助治疗 12 周的疗效、安全性和预测标志物。
J Clin Oncol. 2017 Sep 10;35(26):3046-3054. doi: 10.1200/JCO.2016.71.9815. Epub 2017 Jul 6.
6
Interim [F]Fluorodeoxyglucose-Positron Emission Tomography During Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.人表皮生长因子受体2阳性乳腺癌新辅助治疗期间的中期氟脱氧葡萄糖正电子发射断层扫描
J Clin Oncol. 2019 Aug 10;37(23):2091-2092. doi: 10.1200/JCO.19.00776. Epub 2019 Jun 28.
7
Systemic treatment of patients with early breast cancer: recent updates and state of the art.早期乳腺癌患者的系统性治疗：最新进展和现状。
Breast. 2019 Nov;48 Suppl 1:S7-S20. doi: 10.1016/S0960-9776(19)31115-4.
8
Ado-trastuzumab emtansine for the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer.ado曲妥珠单抗（ado-曲妥珠单抗）用于治疗人表皮生长因子受体2阳性转移性乳腺癌。
Am J Health Syst Pharm. 2014 Apr 1;71(7):537-48. doi: 10.2146/ajhp130342.
9
Substituting adjuvant trastuzumab emtansine for Herceptin improves survival in patients with human epidermal growth factor receptor 2-positive breast cancer.用辅助性曲妥珠单抗恩美曲妥珠单抗替代赫赛汀可提高人表皮生长因子受体2阳性乳腺癌患者的生存率。
Cancer. 2019 Apr 15;125(8):1213. doi: 10.1002/cncr.32088.
10
Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.曲妥珠单抗-美坦新偶联物（T-DM1）联合多西他赛加或不加帕妥珠单抗治疗人表皮生长因子受体 2（HER2）阳性局部晚期或转移性乳腺癌患者的 Ib/IIa 期研究结果。
Ann Oncol. 2016 Jul;27(7):1249-56. doi: 10.1093/annonc/mdw157. Epub 2016 Apr 6.

引用本文的文献

1
"Clinical trials are space travel": Factors of psychological response to recurrence among oncologists enrolling patients in treatment optimization trials.“临床试验犹如太空旅行”：参与优化治疗试验招募患者的肿瘤学家对复发的心理反应因素。
Cancer Med. 2023 Dec;12(23):21490-21501. doi: 10.1002/cam4.6710. Epub 2023 Nov 10.
2
Physician Perspectives on Reducing Curative Cancer Treatment Intensity for Populations Underrepresented in Clinical Trials.医师视角下临床试验代表性不足人群的癌症治疗强度降低问题
Oncologist. 2022 Dec 9;27(12):1067-1073. doi: 10.1093/oncolo/oyac191.
3
Facilitators and barriers to reducing chemotherapy for early-stage breast cancer: a qualitative analysis of interviews with patients and patient advocates.
促进和阻碍早期乳腺癌化疗的因素：对患者和患者权益倡导者进行访谈的定性分析。
BMC Cancer. 2022 Feb 4;22(1):141. doi: 10.1186/s12885-022-09189-w.
4
Clinical trial representativeness and treatment intensity in a real-world sample of women with early stage breast cancer.真实世界早期乳腺癌女性患者临床试验代表性和治疗强度
Breast Cancer Res Treat. 2021 Dec;190(3):531-540. doi: 10.1007/s10549-021-06381-7. Epub 2021 Sep 29.
5
NDUFA4L2 promotes trastuzumab resistance in HER2-positive breast cancer.NDUFA4L2促进HER2阳性乳腺癌对曲妥珠单抗的耐药性。
Ther Adv Med Oncol. 2021 Jun 30;13:17588359211027836. doi: 10.1177/17588359211027836. eCollection 2021.
6
Patient perspectives on chemotherapy de-escalation in breast cancer.患者对乳腺癌化疗降级的看法。
Cancer Med. 2021 May;10(10):3288-3298. doi: 10.1002/cam4.3891. Epub 2021 May 1.
7
Immunotherapy for Breast Cancer Treatment.用于乳腺癌治疗的免疫疗法。
Iran Biomed J. 2021 Mar 8;25(3):140-56. doi: 10.29252/ibj.25.3.140.